The Trump Administration is planning to link the active ingredient in Tylenol to autism, with the intention to warn pregnant women against the use of the medication unless they have a fever, John Tozzi of Bloomberg reports. A Kenvue (KVUE) representative did not immediately have a comment, but the company has previously said there is no causal link between taking acetaminophen during pregnancy and autism.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KVUE:
- Kenvue price target lowered to $20 from $22 at Citi
- Kenvue Stock (KVUE) Up after CEO Met Health Secretary to Kick Tylenol Off Autism Report
- Kenvue lobbied RFK Jr. not to cite Tylenol as autism cause, WSJ reports
- Buy Rating on Kenvue, Inc. Amidst Minimal Legal Risks and Overreaction to Tylenol Concerns
- Kenvue price target lowered to $23 from $25 at Evercore ISI